Skip to main content

Fully Closed-Loop Multiple Model Probabilistic Predictive Controller Artificial Pancreas Performance in Adolescents and Adults in a Supervised Hotel Setting.

Citation
Forlenza, G. P., et al. “Fully Closed-Loop Multiple Model Probabilistic Predictive Controller Artificial Pancreas Performance In Adolescents And Adults In A Supervised Hotel Setting.”. Diabetes Technology & Therapeutics, pp. 335-343.
Center Albert Einstein College of Medicine
Author Gregory P Forlenza, Faye M Cameron, Trang T Ly, David Lam, Daniel P Howsmon, Nihat Baysal, Georgia Kulina, Laurel Messer, Paula Clinton, Camilla Levister, Stephen D Patek, Carol J Levy, Paul Wadwa, David M Maahs, Wayne Bequette, Bruce A Buckingham
Keywords Artificial pancreas, clinical trial, Fully closed-loop, type 1 diabetes
Abstract

BACKGROUND: Initial Food and Drug Administration-approved artificial pancreas (AP) systems will be hybrid closed-loop systems that require prandial meal announcements and will not eliminate the burden of premeal insulin dosing. Multiple model probabilistic predictive control (MMPPC) is a fully closed-loop system that uses probabilistic estimation of meals to allow for automated meal detection. In this study, we describe the safety and performance of the MMPPC system with announced and unannounced meals in a supervised hotel setting.

RESEARCH DESIGN AND METHODS: The Android phone-based AP system with remote monitoring was tested for 72 h in six adults and four adolescents across three clinical sites with daily exercise and meal challenges involving both three announced (manual bolus by patient) and six unannounced (no bolus by patient) meals. Safety criteria were predefined. Controller aggressiveness was adapted daily based on prior hypoglycemic events.

RESULTS: Mean 24-h continuous glucose monitor (CGM) was 157.4 ± 14.4 mg/dL, with 63.6 ± 9.2% of readings between 70 and 180 mg/dL, 2.9 ± 2.3% of readings <70 mg/dL, and 9.0 ± 3.9% of readings >250 mg/dL. Moderate hyperglycemia was relatively common with 24.6 ± 6.2% of readings between 180 and 250 mg/dL, primarily within 3 h after a meal. Overnight mean CGM was 139.6 ± 27.6 mg/dL, with 77.9 ± 16.4% between 70 and 180 mg/dL, 3.0 ± 4.5% <70 mg/dL, 17.1 ± 14.9% between 180 and 250 mg/dL, and 2.0 ± 4.5%> 250 mg/dL. Postprandial hyperglycemia was more common for unannounced meals compared with announced meals (4-h postmeal CGM 197.8 ± 44.1 vs. 140.6 ± 35.0 mg/dL; P < 0.001). No participants met safety stopping criteria.

CONCLUSIONS: MMPPC was safe in a supervised setting despite meal and exercise challenges. Further studies are needed in a less supervised environment.

Year of Publication
2018
Journal
Diabetes technology & therapeutics
Volume
20
Issue
5
Number of Pages
335-343
Date Published
12/2018
ISSN Number
1557-8593
DOI
10.1089/dia.2017.0424
Alternate Journal
Diabetes Technol. Ther.
PMID
29658779
PMCID
PMC5963546
Download citation